Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.58 |
| ▸ | DHODH | Q02127 | 6/20 | 0.48 |
| ▸ | CNR1 | P21554 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13667451 | 0.87 | KMT2A (0.53) | KMT2ACNR1L3MBTL1HPGDCYP1A2 | |
| SCHEMBL5189312 | 0.85 | CNR1 (0.48) | KMT2ADHODHCNR1L3MBTL1HPGD | |
| SCHEMBL1013115 | 0.85 | KMT2A (0.51) | KMT2ADHODHCNR1L3MBTL1MAPT | |
| SCHEMBL8946526 | 0.83 | KMT2A (0.46) | KMT2ADHODHCNR1L3MBTL1HPGD | |
| SCHEMBL2733287 | 0.82 | ALDH1A1 (0.55) | KMT2ADHODHHPGDCYP1A2MAPT | |
| SCHEMBL6016340 | 0.82 | NTRK1 (0.44) | KMT2ANTRK1ALDH1A1 | |
| SCHEMBL8946605 | 0.82 | KMT2A (0.45) | KMT2ADHODHCNR1L3MBTL1ALDH1A1 | |
| SCHEMBL6016328 | 0.82 | RXFP1 (0.53) | KMT2AHPGDMAPTNTRK1MEN1 | |
| SCHEMBL3442759 | 0.82 | HPGD (0.52) | KMT2ADHODHCNR1HPGDMAPT | |
| SCHEMBL25309730 | 0.82 | NTRK1 (0.41) | KMT2AHPGDNTRK1ALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103068814-B | Anthranilic acid derivative | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-11-25 | — | — | CN | disclosed |
| CN-103068814-A | Anthranilic acid derivatives | BAYER CROPSCIENCE AG | 2013-04-24 | — | — | CN | disclosed |
| CN-102883606-A | Hydrazine-substituted anthranilic acid derivatives | BAYER CROPSCIENCE AG | 2013-01-16 | — | — | CN | disclosed |
| CN-102066335-A | Substituted pyrimidin-5-carboxamides 281 | ASTRAZENECA AB | 2011-05-18 | — | — | CN | disclosed |
| EP-2271629-A1 | SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281 | AstraZeneca AB (SE) | 2011-01-12 | — | — | EP | disclosed |
| WO-2009130496-A1 | SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281 | ASTRAZENECA AB (SE) | 2009-10-29 | — | — | WO | disclosed |
| WO-2009130496-A1 | SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281 | ASTRAZENECA AB (SE) | 2009-10-29 | — | — | WO | disclosed |
| US-20090264401-A1 | SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281 | ASTRAZENECA AB (SE) | 2009-10-22 | — | — | US | disclosed |
| US-20090264401-A1 | SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281 | ASTRAZENECA AB (SE) | 2009-10-22 | — | — | US | disclosed |
| US-20090264401-A1 | SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281 | ASTRAZENECA AB (SE) | 2009-10-22 | — | — | US | disclosed |
| US-5500424-A | ENZYME INHIBITORS | NIHON NOHYAKU CO., LTD. (JP) | 1996-03-19 | — | — | US | disclosed |
| EP-0638557-A1 | N-phenylpyri(mi)dine-N'-phenyl-urea derivatives, their preparation and their use as ACAT inhibitors | NIHON NOHYAKU CO., LTD. (JP) | 1995-02-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264401-A1 | SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281 | CYP2S1, HSD11B1, HSD3B1 | KMT2A 1860/4885DHODH 60/4885CNR1 559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.